Given how much attention SPACs and IPOs receive in the business news, it seems like what happens when a company goes public would be … well, public knowledge. In reality, the process of taking a company public isn’t as transparent as it might seem. For one, there are several paths to going public. Factor in the time-consuming process of negotiating, meeting mandatory requirements and promoting the public business and those who skim the finance news for stock tips lose interest.

Explore the latest IPO & Public Listing Report

"Enthusiastically we close the door on 2022; a year filled with SPAC liquidations and withdrawals, merger terminations, and very few IPOs. We expect the IPO window to open in 2023 with high-quality growth companies bringing much needed inspiration to the capital markets."

Craig Clay, President, Donnelley Financial Solutions

Life Science Sales Director, Luke Marshall from EMEA, provides his insight on the future of SPACs and how the process is still promising for biopharma companies to go public.

"The Insider by DFIN" is a series of video interviews featuring the latest trends, topics and key perspectives on the global capital markets.

Join DFIN President and CEO Dan Leib as he shares his insights on DFIN’s transformation and future growth strategy in this special podcast edition of The Insider by DFIN.

"The Insider by DFIN" is a series of video interviews featuring the latest trends, topics and key perspectives on the global capital markets.

Join DFIN President of Global Capital Markets Craig Clay as he shares his insights on impacts of current global events on public and private markets today.

SEC Commissioner Hester M. Pierce previously argued, “We should be using the moment to ask whether the SPAC revival of recent years reveals shortcoming with the traditional IPO process and to consider ways to calibrate properly the rules governing IPOs, SPACs, and Direct Listings." This week, the U.S.

The past 12 months have been a whirlwind of M&A activity & public debuts. As many companies prepared to go public and wrestled over whether to do a traditional IPO or merge with a SPAC, several public companies moved in the opposite direction. They announced they were going private.

In fact, some experts are now predicting that the flood of IPOs and SPACs will be replaced by a surge in companies leaving the public markets. Companies including our own clients Houghton Mifflin, Citrix, and MoneyGram have already chosen this option.

The global capital markets saw a spike in popularity in IPOs of special purpose acquisition companies (SPACs), particularly in the U.S. where SPAC listings have grown exponentially in the past few years.

DFIN announced its fourth quarter and full-year earnings on Tuesday. You can read the press announcement here.

“The Insider by DFIN” is a series of video interviews featuring latest topics and key perspectives on the global capital markets.

It has been said that we are at the front end of an explosion of science--and that this is "the century" of biology. There is no question or doubt that the COVID-19 pandemic accelerated the Life Sciences industry—and that speed of innovation is nothing short of remarkable and unparalleled.